Improving affordability of new essential cancer medicines

The Lancet Oncology

11 July 2019 - Effective cancer care requires investment in health infrastructure, a trained health workforce, and quality-assured, affordable medicines within a sustainable supply chain. 

To this end, in a major move to increase access to cancer medicines in low-income and middle-income countries (LMICs), WHO has added ten new cancer therapies to its 21st Model List of Essential Medicines.

When WHO labels medicines as essential, it means that they have proven their utility and should be available and affordable to all. Therefore, these medicines should be included in national essential medicines lists, which would enable governments to use scarce resources to select medicines more effectively.

Read The Lancet Oncology article

Michael Wonder

Posted by:

Michael Wonder